We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Allergan plc | NYSE:AGN | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 193.02 | 0 | 01:00:00 |
DUBLIN, April 26, 2016 /PRNewswire/ -- Allergan (NYSE: AGN) today announced that its data will be presented during the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, Washington, May 1-5, 2016.
Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO
This data spans retina, ocular surface and glaucoma subspecialties and is reflective of Allergan's global leadership position in eye care.
"Allergan is pleased to be presenting data at ARVO this year. With more than 60 years of eye care experience and 17 mid-to-late stage programs in development, Allergan is committed to advancing research and products for the eye care community," said David Nicholson, Executive Vice President and President of Global R&D Brands at Allergan.
The scheduled times (noted in local Pacific Time) of the 18 Allergan presentations, presentation titles and locations at the Washington State Convention Center are as follows:
Retina:
Ocular Surface:
Glaucoma:
About Allergan
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.
For more information, visit Allergan's website at www.allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 (certain of such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
CONTACTS:
Investors:
Lisa DeFrancesco
(862) 261-7152
Media:
Mark Marmur
(973) 906-1526
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/allergan-presents-data-at-the-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting-in-seattle-300257241.html
SOURCE Allergan plc
Copyright 2016 PR Newswire
1 Year Allergan Chart |
1 Month Allergan Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions